S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
NASDAQ:REGN

Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis

$982.82
+16.73 (+1.73%)
(As of 03/1/2024 ET)
Today's Range
$966.09
$988.13
50-Day Range
$846.72
$993.35
52-Week Range
$684.80
$998.33
Volume
370,542 shs
Average Volume
486,690 shs
Market Capitalization
$107.87 billion
P/E Ratio
28.28
Dividend Yield
N/A
Price Target
$942.41

Regeneron Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
4.1% Downside
$942.41 Price Target
Short Interest
Healthy
1.25% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.69
Upright™ Environmental Score
News Sentiment
0.49mentions of Regeneron Pharmaceuticals in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$12.50 M Sold Last Quarter
Proj. Earnings Growth
4.08%
From $38.50 to $40.07 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.82 out of 5 stars

Medical Sector

244th out of 950 stocks

Pharmaceutical Preparations Industry

106th out of 431 stocks


REGN stock logo

About Regeneron Pharmaceuticals Stock (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

REGN Stock Price History

REGN Stock News Headlines

REGN Mar 2024 1050.000 call
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
REGN Mar 2024 930.000 put
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
REGN Feb 2024 957.500 put
REGN Feb 2024 965.000 put
REGN Feb 2024 952.500 call
2 No-Brainer Biotech Stocks to Buy Right Now
REGN Mar 2024 910.000 put
See More Headlines
Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/02/2024
Today
3/02/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:REGN
CUSIP
75886F10
Employees
13,450
Year Founded
1988

Price Target and Rating

Average Stock Price Target
$942.41
High Stock Price Target
$1,184.00
Low Stock Price Target
$680.00
Potential Upside/Downside
-4.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
24 Analysts

Profitability

Net Income
$3.95 billion
Pretax Margin
32.01%

Debt

Sales & Book Value

Annual Sales
$13.12 billion
Cash Flow
$44.01 per share
Book Value
$236.63 per share

Miscellaneous

Free Float
100,070,000
Market Cap
$107.87 billion
Optionable
Optionable
Beta
0.11

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Should I Buy Regeneron Pharmaceuticals Stock? REGN Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Regeneron Pharmaceuticals was last updated on Thursday, February 29, 2024 at 1:44 PM.

Pros

Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.:

  • Regeneron Pharmaceuticals has a strong product portfolio, including EYLEA injection for various eye diseases, which has shown significant success in the market.
  • The company has a history of consistent growth and innovation in the biopharmaceutical sector, attracting investors looking for long-term potential.
  • Recent increase in institutional investments and hedge funds ownership indicates confidence in the company's future performance.
  • Regeneron Pharmaceuticals' stock price has been relatively stable and has shown resilience during market fluctuations, providing a sense of security to investors.
  • The company's focus on discovering, inventing, and developing medicines for treating various diseases worldwide positions it well in the healthcare industry.

Cons

Investors should be bearish about investing in Regeneron Pharmaceuticals, Inc. for these reasons:

  • Regeneron Pharmaceuticals operates in a highly competitive industry with rapid technological advancements, leading to potential challenges in maintaining market share.
  • The biopharmaceutical sector is subject to regulatory scrutiny and changes, which could impact the company's operations and financial performance.
  • Market volatility and economic uncertainties may affect the company's stock price, posing risks to investors seeking short-term gains.
  • Dependency on a few key products, such as EYLEA injection, for a significant portion of revenue could expose the company to risks associated with product concentration.
  • Investors should carefully monitor any developments in the healthcare landscape that could impact Regeneron Pharmaceuticals' market position and growth prospects.














REGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?

24 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 18 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" REGN shares.
View REGN analyst ratings
or view top-rated stocks.

What is Regeneron Pharmaceuticals' stock price target for 2024?

24 brokerages have issued 12-month price targets for Regeneron Pharmaceuticals' shares. Their REGN share price targets range from $680.00 to $1,184.00. On average, they predict the company's share price to reach $942.41 in the next year. This suggests that the stock has a possible downside of 4.1%.
View analysts price targets for REGN
or view top-rated stocks among Wall Street analysts.

How have REGN shares performed in 2024?

Regeneron Pharmaceuticals' stock was trading at $878.29 at the beginning of 2024. Since then, REGN stock has increased by 11.9% and is now trading at $982.82.
View the best growth stocks for 2024 here
.

When is Regeneron Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our REGN earnings forecast
.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its quarterly earnings data on Friday, February, 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping the consensus estimate of $10.73 by $1.13. The biopharmaceutical company had revenue of $3.43 billion for the quarter, compared to analysts' expectations of $3.29 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 17.61% and a net margin of 30.14%. Regeneron Pharmaceuticals's revenue was up .6% compared to the same quarter last year. During the same period last year, the business posted $10.96 EPS.
Read the conference call transcript
.

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.11%), Capital World Investors (4.71%), Capital International Investors (2.68%), Dodge & Cox (2.16%), Putnam Investments LLC (1.11%) and Norges Bank (0.97%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends
.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Regeneron Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More
This page (NASDAQ:REGN) was last updated on 3/2/2024 by MarketBeat.com Staff